Patents by Inventor Shugene Lynn

Shugene Lynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
    Publication number: 20240083981
    Abstract: The present invention relates to the treatment of herpes simplex virus (HSV) infection using an anti-HSV antibody. In particular, the anti-HSV antibody specifically binds to the glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). The treatment of the present invention is effective against drug-resistant and/or recurrent HSV infection.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 14, 2024
    Applicant: United BioPharma, Inc.
    Inventors: Be-Sheng KUO, Chao-Hung LI, Hsiao-Yun SHAO, Yaw-Jen LIU, Shugene LYNN, Chang Yi WANG
  • TREATMENT OF IGE-MEDIATED DISEASES
    Publication number: 20230122862
    Abstract: The present invention relates to the treatment of IgE mediated diseases using an anti-IgE antibody. In particular, the anti-IgE antibody is a multifunctional antibody against IgE, which neutralizes IgE and inhibits IgE synthesis. Specifically, the treatment of the present invention is effective in providing a rapid and/or sustained suppression of disease symptoms.
    Type: Application
    Filed: October 12, 2022
    Publication date: April 20, 2023
    Applicant: United BioPharma, Inc.
    Inventors: Be-Sheng KUO, Chao-Hung LI, Ywan-Feng LI, Shugene LYNN, Chang Yi WANG
  • Deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
    Patent number: 7872110
    Abstract: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: January 18, 2011
    Assignee: United Biomedical, Inc.
    Inventors: Shugene Lynn, Chang Yi Wang
  • Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
    Patent number: 7501494
    Abstract: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: March 10, 2009
    Assignee: United Biomedical, Inc.
    Inventors: Shugene Lynn, Chang Yi Wang
  • DEIMMUNIZED MONOCLONAL ANTIBODIES FOR PROTECTION AGAINST HIV EXPOSURE AND TREATMENT OF HIV INFECTION
    Publication number: 20090060914
    Abstract: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement.
    Type: Application
    Filed: September 9, 2008
    Publication date: March 5, 2009
    Inventors: Shugene Lynn, Chang Yi Wang
  • Peptide-based diagnostic reagents for SARS
    Publication number: 20050214748
    Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.
    Type: Application
    Filed: November 8, 2004
    Publication date: September 29, 2005
    Inventors: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia
  • Peptide-based diagnostic reagents for SARS
    Publication number: 20050100883
    Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.
    Type: Application
    Filed: November 12, 2003
    Publication date: May 12, 2005
    Inventors: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia
  • Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
    Publication number: 20040137000
    Abstract: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 15, 2004
    Inventors: Shugene Lynn, Chang Yi Wang